- Home
- SNT vs CRBU Comparison
SNT vs CRBU Comparison
Compare SNT & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- CRBU
- Stock Information
- Founded
- SNT 1965
- CRBU 2011
- Country
- SNT Canada
- CRBU United States
- Employees
- SNT N/A
- CRBU N/A
- Industry
- SNT Telecommunications Equipment
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- SNT Telecommunications
- CRBU Health Care
- Exchange
- SNT Nasdaq
- CRBU Nasdaq
- Market Cap
- SNT 80.4M
- CRBU 93.0M
- IPO Year
- SNT 1993
- CRBU 2021
- Fundamental
- Price
- SNT $3.38
- CRBU $0.84
- Analyst Decision
- SNT
- CRBU Strong Buy
- Analyst Count
- SNT 0
- CRBU 5
- Target Price
- SNT N/A
- CRBU $11.80
- AVG Volume (30 Days)
- SNT 19.3K
- CRBU 971.0K
- Earning Date
- SNT 04-21-2025
- CRBU 03-10-2025
- Dividend Yield
- SNT N/A
- CRBU N/A
- EPS Growth
- SNT N/A
- CRBU N/A
- EPS
- SNT 0.06
- CRBU N/A
- Revenue
- SNT $34,455,000.00
- CRBU $9,994,000.00
- Revenue This Year
- SNT N/A
- CRBU $3.50
- Revenue Next Year
- SNT N/A
- CRBU $177.84
- P/E Ratio
- SNT $59.51
- CRBU N/A
- Revenue Growth
- SNT 2.04
- CRBU N/A
- 52 Week Low
- SNT $1.08
- CRBU $0.84
- 52 Week High
- SNT $3.97
- CRBU $4.97
- Technical
- Relative Strength Index (RSI)
- SNT 42.93
- CRBU 32.10
- Support Level
- SNT $3.42
- CRBU $0.88
- Resistance Level
- SNT $3.54
- CRBU $1.01
- Average True Range (ATR)
- SNT 0.10
- CRBU 0.08
- MACD
- SNT 0.00
- CRBU 0.00
- Stochastic Oscillator
- SNT 30.77
- CRBU 2.01
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.